Cited 0 times in
Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김유선 | - |
dc.date.accessioned | 2014-12-18T08:37:11Z | - |
dc.date.available | 2014-12-18T08:37:11Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0902-0063 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/86644 | - |
dc.description.abstract | BACKGROUND: The association between clinical events and everolimus exposure in patients receiving reduced-exposure calcineurin inhibitor therapy is poorly explored. METHODS: In a pre-planned, descriptive analysis of data from a randomized controlled trial, events were correlated with everolimus trough concentrations in 556 newly transplanted kidney transplant patients receiving everolimus with reduced-exposure cyclosporine (CsA) and steroids. Influence of everolimus exposure on clinical events was stratified according to predefined time-normalized concentrations. RESULTS: The incidence of treated biopsy-proven acute rejection and graft loss at month 12 was highest in patients with everolimus <3 ng/mL (36.4% and 28.6%, respectively, vs. 9.1-15.3% and 0.9-5.0% with higher concentration ranges). A higher mortality rate was observed in patients with an everolimus trough concentration ≥ 12 ng/mL (10.0% vs. 1.7-5.6% with lower concentration ranges). The lowest rates of renal dysfunction (defined as poor renal function [estimated GFR, serum creatinine] or proteinuria), wound healing events, peripheral edema, new-onset diabetes mellitus, hypercholesterolemia and hypertriglyceridemia were generally observed with everolimus trough concentration in the range 3-8 ng/mL and CsA <100 ng/mL. Proteinuria occurred most frequently in patients with very low or very high everolimus trough concentrations. CONCLUSIONS: These results support an exposure-response relationship between clinical events and everolimus trough concentrations in kidney transplant patients receiving reduced-exposure CsA. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | CLINICAL TRANSPLANTATION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Cyclosporine/administration & dosage* | - |
dc.subject.MESH | Cyclosporine/adverse effects | - |
dc.subject.MESH | Cyclosporine/pharmacokinetics | - |
dc.subject.MESH | Cyclosporine/therapeutic use | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Drug Monitoring | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Everolimus | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Graft Rejection/epidemiology | - |
dc.subject.MESH | Graft Rejection/prevention & control* | - |
dc.subject.MESH | Graft Survival | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents/administration & dosage | - |
dc.subject.MESH | Immunosuppressive Agents/adverse effects | - |
dc.subject.MESH | Immunosuppressive Agents/pharmacokinetics | - |
dc.subject.MESH | Immunosuppressive Agents/therapeutic use* | - |
dc.subject.MESH | Kidney Transplantation* | - |
dc.subject.MESH | Linear Models | - |
dc.subject.MESH | Logistic Models | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Postoperative Complications/chemically induced | - |
dc.subject.MESH | Postoperative Complications/epidemiology | - |
dc.subject.MESH | Postoperative Complications/prevention & control* | - |
dc.subject.MESH | Sirolimus/adverse effects | - |
dc.subject.MESH | Sirolimus/analogs & derivatives* | - |
dc.subject.MESH | Sirolimus/pharmacokinetics | - |
dc.subject.MESH | Sirolimus/therapeutic use | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Fuad S. Shihab | - |
dc.contributor.googleauthor | Diane Cibrik | - |
dc.contributor.googleauthor | Laurence Chan | - |
dc.contributor.googleauthor | Yu Seun Kim | - |
dc.contributor.googleauthor | Mario Carmellini | - |
dc.contributor.googleauthor | Rowan Walker | - |
dc.contributor.googleauthor | Gazi Zibari | - |
dc.contributor.googleauthor | James Pattison | - |
dc.contributor.googleauthor | Catherine Cornu-Artis | - |
dc.contributor.googleauthor | Zailong Wang | - |
dc.contributor.googleauthor | Helio Tedesco-Silva Jr | - |
dc.identifier.doi | 10.1111/ctr.12045. | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00785 | - |
dc.relation.journalcode | J00615 | - |
dc.identifier.eissn | 1399-0012 | - |
dc.identifier.pmid | 23230975 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/ctr.12045/abstract | - |
dc.subject.keyword | Calcineurin inhibitor toxicity | - |
dc.subject.keyword | Cyclosporine | - |
dc.subject.keyword | Everolimus | - |
dc.subject.keyword | Renal function | - |
dc.subject.keyword | Renal transplantation | - |
dc.contributor.alternativeName | Kim, Yu Seun | - |
dc.contributor.affiliatedAuthor | Kim, Yu Seun | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 27 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 217 | - |
dc.citation.endPage | 226 | - |
dc.identifier.bibliographicCitation | CLINICAL TRANSPLANTATION, Vol.27(2) : 217-226, 2013 | - |
dc.identifier.rimsid | 29116 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.